Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial

Lancet

Volumn 358, Issue 9286, 2001, Pages 958-965

  Manns, Michael P ^a   McHutchison, John G ^b   Gordon, Stuart C ^c   Rustgi, Vinod K ^d   Shiffman, Mitchell ^e   Reindollar, Robert ^f   Goodman, Zachary D ^g   Koury, Kenneth ^h   Ling, Mei Hsiu ^h   Albrecht, Janice K ^h  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SCRIPPS CLINIC   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Charlotte GI/Liver Disease Clinic   (United States)

^g ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0035934568     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)06102-5     Document Type: Article

References (21)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C
3. Long-term mortality after transfusion associated non-A, non-B hepatitis
4. Clinical outcomes after transfusion-associated hepatitis C
5. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
6. Liver transplantation for chronic viral hepatitis
7. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
8. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
9. Pegylated interferon alfa-2b: Pharmacokinetics, phamacodynamics, safety and preliminary efficacy data
10. Peginterferon alfa-2a in patients with chronic hepatitis C
11. A randomised, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C
12. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
13. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C
14. Prediction of response during interferon alfa-2b in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
15. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
16. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
17. Histopathology of hepatitis C virus infection
18. Multicenter, randomized controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin
19. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation
20. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
21. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers